This is a continuation of an existing, well-functioning, and absolutely essential Core. Over its lifetime, Core A (National Tissue Resource) has provided a very large number of tissues to SPORE and non-SPORE investigators alike, nationally and even internationally. During our first 9 years, from 1993 through 2001, a total of 10,866 tumor samples were delivered to 78 projects. Investigators in this SPORE accounted for only about 40% of that activity ? more than 6,000 specimens were provided to 59 different investigators outside the SPORE. Since the last submission (2002 to 2006), the Core has provided 5,057 specimens (with an additional 1320 pending distribution) to 34 projects involving 17 different principal investigators. A large fraction of distributions continue to go to investigators outside of our own SPORE. At least 25 full length manuscripts directly related to use of specimens and/or data from our SPORE tissue resources have been published since the last submission. The continuing objectives of the National Tissue Resource Core are to provide centralized support for tissue banking, quality assessment, and distribution efforts within the Breast SPORE by managing and distributing tissue and data from legacy inventories to qualified researchers;by collecting, managing, and distributing newly acquired breast cancer materials to qualified researchers;by assisting in acquisition, management, and distribution of clinical trial associated material;and by collection of additional clinical and follow-up data on appropriately consented subjects represented in the collections. Although guidelines state that """"""""each SPORE must have a dedicated core for collection and distribution of human cancer specimens"""""""", Core A greatly surpasses this minimum requirement ? it is critical for the research activities proposed in this SPORE, and also has been and will continue to be an important research resource to other scientists within and outside Baylor College of Medicine who are engaged in translational breast cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058183-15
Application #
8182283
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-12-01
Budget End
2009-11-30
Support Year
15
Fiscal Year
2009
Total Cost
$150,156
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 306 publications